Erlotinib in non-small cell lung cancer

Masayuki Takeda, Isamu Okamoto

Research output: Contribution to journalArticle

Abstract

Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.

Original languageEnglish
Pages (from-to)896-900
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number6
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Quinazolines
Mutation
Disease-Free Survival
Hypersensitivity
Survival Rate
Drug Therapy
Erlotinib Hydrochloride
gefitinib
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Erlotinib in non-small cell lung cancer. / Takeda, Masayuki; Okamoto, Isamu.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 6, 01.01.2011, p. 896-900.

Research output: Contribution to journalArticle

@article{045148539e9b4c82877943a31d200d9b,
title = "Erlotinib in non-small cell lung cancer",
abstract = "Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.",
author = "Masayuki Takeda and Isamu Okamoto",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "38",
pages = "896--900",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Erlotinib in non-small cell lung cancer

AU - Takeda, Masayuki

AU - Okamoto, Isamu

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.

AB - Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84867001737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867001737&partnerID=8YFLogxK

M3 - Article

C2 - 21677478

AN - SCOPUS:84867001737

VL - 38

SP - 896

EP - 900

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -